Class II Transactivator Gene (

CIITA gene bare lymphocyte syndrome II compound heterozygote mutation inborn errors of immunity primary immunodeficiency

Journal

The application of clinical genetics
ISSN: 1178-704X
Titre abrégé: Appl Clin Genet
Pays: New Zealand
ID NLM: 101579789

Informations de publication

Date de publication:
2024
Historique:
received: 08 04 2024
accepted: 12 09 2024
medline: 30 9 2024
pubmed: 30 9 2024
entrez: 30 9 2024
Statut: epublish

Résumé

Inborn errors of immunity (IEI) are disorders that present a health issue, especially in developing countries where there is a high rate of consanguineous marriages and an increasing rate of diagnosis. One of these disorders is Bare Lymphocyte Syndrome II (BLS II) which is a rare and genetically complex disease that has high morbidity and mortality. The exact genotypic and phenotypic characteristics are still poorly characterized especially in developing countries. Here, we report the first case of BLS II in a seven-month-old Sudanese female with recurrent chest infections, dermatitis, persistent diarrhea, and failure to thrive. The patient's all four sisters and three paternal uncles died in early infancy. Laboratory investigations revealed low CD3+, CD4+, and CD8+ lymphocytes, along with normal CD19+ and CD16+ lymphocytes, and low serum IgM and IgA levels. Genetic analysis revealed two Further bioinformatics, immunological and clinical workups supported a pathogenic effect of both mutations affecting the function of CIITA protein, and suggesting a compound heterozygote mutation. The patient was started on prophylactic antibiotics and regular intravenous immunoglobulin replacement therapy. The prognosis of this disease is poor in most of the cases, with only a few reported cases surviving until adulthood.

Identifiants

pubmed: 39347515
doi: 10.2147/TACG.S472788
pii: 472788
pmc: PMC11430264
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Pagination

133-141

Informations de copyright

© 2024 Salih et al.

Déclaration de conflit d'intérêts

The authors report no conflict of interest.

Auteurs

Omaima Abdel Majeed Mohamed Salih (OAMM)

Departments of Pediatrics, Faculty of Medicine, Omdurman Islamic University, Omdurman, Sudan.
Pediatric Clinical Immunologist, Tropical Disease Teaching Hospital, Omdurman, Sudan.

Nahla Hashim Hassan Erwa (NHH)

Clinical Immunology Consultant, Faculty of Medicine & Soba University Hospital, University of Khartoum, Khartoum, Sudan.

Abdelrahman Hamza Abdelmoneim (AH)

Faculty of Medicine, Al-Neelain University, Khartoum, Sudan.

Hiba Awadelkareem Osman Fadl (HAO)

Department of Hematology, Faculty of Medical Laboratory Sciences, Al-Neelain University, Khartoum, Sudan.
Senior Medical Laboratory Specialist, Saudi Commission for Health Specialties (SCFHS), Makkah, Kingdom of Saudi Arabia.

Brigitte Glanzmann (B)

DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, 7505, South Africa.
South African Medical Research Council (SAMRC) Genomics Platform, Cape Town, 7505, South Africa.

Manasik Abdalla Babiker Osman (MAB)

Faculty of Medicine, University of Bahri, Khartoum, Sudan.

Monzir Ahmed Hassan Osman (MAH)

Faculty of Medicine and Health Sciences, Omdurman Islamic University, Khartoum, Sudan.

Thuraya Mohamed Elshiekh Gasim (TME)

Faculty of Medicine and Health Sciences, Omdurman Islamic University, Khartoum, Sudan.

Alamin Mustafa (A)

Faculty of Medicine, Al-Neelain University, Khartoum, Sudan.

Classifications MeSH